Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  PuriCore plc    PURI   GB00B3XBCR18

Delayed Quote. Delayed  - 05/27 05:35:17 pm
23 GBp   -2.13%
05/27 PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticid..
04/14 PURICORE : Appointment of Dr. Christian Peters as Chief Medical Offi..
04/14 PURICORE : Appoints Christian Peters As Chief Medical Officer
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

PuriCore plc : PuriCore Raises $3.5 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2012 | 09:11pm CEST
PuriCore plc ("PuriCore" or the "Company" or the "Group") PuriCore Raises $3.5 Million MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 January 2012 - PuriCore (LSE: PURI), the water- based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it closed on a new $3.5 million debt facility with Republic Bank on 29 December 2011. The debt will be utilized to finance the working capital requirements associated with Sterilox Fresh and FloraFresh System installations in H1 2012. The facility is structured as a promissory note with an imputed interest rate of 4%. Enquiries:

FTI Consulting Susan Quigley Ben Brewerton

+44 (0) 20 7831 3113

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on PURICORE PLC
05/27 PURICORE : To Stop Selling ProduceFresh Until Registered As Pesticide
04/14 PURICORE : Appointment of Dr. Christian Peters as Chief Medical Officer
04/14 PURICORE : Appoints Christian Peters As Chief Medical Officer
03/29 PURICORE : CEO Buys 100,000 Shares (DIRECTOR DEALINGS)
03/29 PURICORE : Good progress
03/29 PURICORE : Good progress Biopharmaceutical company PuriCore,
03/24 PURICORE : Considers Spin-Off Of Supermaket Retail Unit As Revenue Rises
03/01 PURICORE : Appoints Balkrishan Gill To Board As Non-Executive
02/09 PURICORE : stronger Biopharmaceutical company PuriCore
02/09 PURICORE : stronger
Advertisement
News chart
Full-screen chart